Lung Cancer News

The addition of eftilagimod alpha to pembrolizumab conferred a 40% overall response rate among patients with non-small cell lung cancer unselected for PD-L1, a cohort analysis of the phase 2 TACTI-002 trial showed.

Precision medicine has shown great potential to improve treatment outcomes and prolong survival of patients with lung cancer, as biomarker-driven therapies continue to extend their reach in this space.

The arthrobacter luteus/albumin ratio demonstrated a strong dose-response relationship with overall lung cancer risk and may be helpful in identifying individuals who should undergo screening, according to study results published in Chest.

Use of different antibody-drug conjugates resulted in a variety of significant and in some cases serious treatment‐associated adverse events, according to results of a systematic review and meta-analysis published in Cancer.

Lung Cancer Awareness Month, observed every November, is intended to educate the public about the potential causes and risk factors of the disease.

Scientists from Denmark and the United States have engineered a yeast commonly used in foods to produce the precursor molecules for the anticancer agent vinblastine, a drug that has been in shortage several times in recent years.

More than 2 years after the COVID-19 pandemic began, new treatments, vaccines and preventive measures have improved safety and disease outcomes for patients with cancer, according to a speaker at Chemotherapy Foundation Symposium.

High levels of racial and economic segregation appeared associated with higher cancer mortality rates across more than 3,000 U.S. counties, according to results of an ecological study.

Less than 6% of eligible Americans have undergone lung cancer screening, according to American Lung Association’s 2022 State of Lung Cancer report.

New treatments for emerging targets have expanded the armamentarium in lung cancer, according to a speaker at Chemotherapy Foundation Symposium.